SIMA AMAN: Open Payments
NPI 1689396293 · GARDENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$894 in 37 payments from 13 companies in 2025. Trend: 2023 $1,300 · 2024 $1,236 · 2025 $894
Food & beverage: $894
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $185 |
| Otsuka America Pharmaceutical, Inc. | 7 | $184 |
| Neurocrine BioSciences, Inc. | 3 | $107 |
| Vanda Pharmaceuticals Inc. | 4 | $106 |
| ABBVIE INC. | 4 | $68 |
| E.R. Squibb & Sons, L.L.C. | 2 | $56 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Tris Pharma Inc | 2 | $34 |
| Lundbeck LLC | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
Products named: REXULTI, INVEGA SUSTENNA, INGREZZA, FANAPT, SPRAVATO, VRAYLAR, COBENFY, Auvelity.
Industry payments across CA — which companies pay providers there.
